Open access peer-reviewed chapter

Platelets in the Newborn

Written By

Ijeoma Esiaba, Iman Mousselli, Giulia M. Faison, Danilyn M. Angeles and Danilo S. Boskovic

Submitted: 13 September 2018 Reviewed: 07 May 2019 Published: 02 September 2019

DOI: 10.5772/intechopen.86715

Chapter metrics overview

1,063 Chapter Downloads

View Full Metrics


Platelets were first described in the mid-nineteenth century. Since then, their roles were identified in hemostasis and thrombosis, inflammation, leukocyte interactions, angiogenesis, and cancer growth. But there is little information about such platelet functions in the newborn. Several studies highlighted some platelet differences between newborns and adults. Yet, in spite of these differences, healthy newborns appear to be adequately protected. A number of factors, however, were reported to negatively affect neonatal platelets. These include maternal hypertensive disorders or infections, neonatal asphyxia or respiratory distress, therapies such as ampicillin or indomethacin, and treatment modalities such as ventilators, nitric oxide, or extracorporeal membrane oxygenation (ECMO). Their effects on newborn platelets are usually transitory, lasting from several hours to a few days or weeks. If these effects are well characterized, they could serve as reporters for diagnosis and monitoring during therapy. Careful studies of neonatal platelets are needed to improve the understanding of basic physiology and pathophysiology in this cohort and to identify possible targets for intervention and therapy.


  • platelet function
  • hemostasis
  • prematurity
  • platelet transfusion
  • newborn
  • sepsis
  • ECMO

1. Introduction

Platelets are small discoid cellular particles, produced by megakaryocytes, and best known for their role in thrombus or platelet plug formation. Since their initial description in the mid-nineteenth century, further details have emerged about their structure and function. More recently, their roles in processes as wide ranging as tissue repair and wound healing, angiogenesis, tumor killing, tumor growth and metastasis, inflammation, and host defense have come to light [1, 2]. Platelets perform these varied functions and diverse interactions because of several receptors and ligands on their surface, and a store of over 300 proteins within their cytoplasm and granules. With newer technological advances, more platelet functions were discovered and the mechanisms for some of them are now clearer.

Platelets mediate primary hemostasis, a dynamic process involving several reactions resulting in thrombus formation. Initially, platelets aggregate to form a platelet plug at the site of injury [3, 4]. In secondary hemostasis, thrombin is generated after a cascade of enzymatic reactions. The generated thrombin subsequently cleaves fibrinogen to fibrin [5]. Fibrin spontaneously polymerizes forming a fibrous network which stabilizes the platelet plug [6]. The process of tertiary hemostasis, or fibrinolysis, restricts clot formation to the site of injury, dissolves clots after the damaged endothelium has been repaired, and prevents the formation of pathologic thrombi [7, 8]. These reactions are tightly regulated to minimize the risk of either bleeding or thrombosis. Components of the hemostatic system are usually preformed and circulate in their respective inactive forms. Apart from their role in hemostasis, some of these factors also play a role in other physiological processes such as embryonic development, angiogenesis, or immunity [9].

Most of the information about platelets is based on studies conducted in adults or in animal models. Despite recognized roles of platelets in processes as wide ranging as inflammation and angiogenesis, information about these roles of neonatal platelets is limited. However, clinical observations suggest that there likely are some functional differences between neonatal and adult platelets. Newborns are at greater risk of contracting infections and may not cope adequately with inflammatory stresses [10]. New blood vessels are formed to meet the demands of rapidly growing tissues. The roles of platelets in these processes and reactions in the newborn are not yet well described. Additionally, certain prematurity-related morbidities such as intraventricular hemorrhage, retinopathy of prematurity, and necrotizing enterocolitis are associated with bleeding and inflammation [11, 12]. Platelets or their functional deficits are believed to be involved in these disorders. Studying platelet function in the newborn is difficult, but emerging methodological approaches requiring small volumes of newborn’s blood are making such studies feasible. Following a general description of platelet structure and functions, this review will highlight documented differences in the newborn.


2. Platelet structure and functions

Platelets mediate primary hemostasis and play roles in procoagulant and fibrinolytic processes [13]. They are nonnucleated fragments derived from bone marrow megakaryocytes. The adult human produces about 1011 platelets daily, rising by more than 20-fold during increased need [14]. In the fetus and neonate, platelets are produced largely in the liver and spleen [15, 16]. Thrombopoietin maintains platelet homeostasis by regulating thrombopoiesis [17, 18]. The resting platelet is disk shaped with a diameter of about 1.5 μm and a lifespan of 7–10 days [19]. Its surface does not promote coagulation or aggregation. In circulation, the platelets’ resting state is further supported by the release of prostacyclin and nitric oxide from endothelial cells, by the expression of CD39 (an ADPase) on the endothelial surface, and by the inability of normal plasma vWF to bind spontaneously to the platelet surface [20].

Platelets have a complex internal structure with a series of organelles. Lacking a nucleus, they nevertheless contain some nucleic acid in the form of ribonucleic acid (RNA), which is used for synthesis of new proteins, especially during or after platelet activation [21]. The secretory granules comprise the α-granules and dense or δ-granules. The α-granules contain adhesion molecules important for platelet interactions with other platelets and blood cells, angiogenic and mitogenic factors, plasma proteins, and several factors relevant for coagulation and fibrinolysis [22]. The dense- or δ-granules contain non-protein molecules such as adenosine diphosphate (ADP), adenosine triphosphate (ATP), calcium and serotonin [22]. These play central roles in amplification of platelet activation and aggregation and in modulation of vascular endothelium and leukocyte functions. Within lysosomes are membrane proteins and acid hydrolases that digest the material in platelet aggregates through hydrolytic degradation [23]. Over 300 proteins are secreted from these granules during activation [24]. In the unstimulated platelets, the granule contents remain internalized. When stimulated, however, platelets release such contents through an open canalicular system [25].

A number of factors and agonists can stimulate platelets. These include shear stress during blood flow, agonists such as thrombin, collagen, or ADP, and recognition of and interaction with viruses, bacteria, or damaged vascular endothelium [26, 27]. Typically, platelet activation is triggered when there is a break in the vascular endothelium. The activated platelets first adhere to the damaged endothelium by binding to von Willebrand factor (vWF) through its surface membrane glycoprotein Ib (GPIb). Further interactions of platelet glycoprotein VI (GPVI) with fibrillary collagen and platelet β1 integrin with laminin, collagen, and fibronectin maintain platelet adhesion to exposed extracellular matrix [8].

Following activation, platelet membrane phospholipid distribution changes to include exposure of phosphatidylserine on the outer surface, thus promoting the condensation of vitamin K-dependent coagulation factors on this surface, and inducing the activation of the procoagulant cascade [28]. Additionally, a rearrangement of the cytoskeleton leads to a change in platelet structure [29] from the resting discoid form, via an intermediate spherical shape, to a fully activated amoeboid form with numerous extending pseudopodia able to interact with some nearby surfaces [29]. Meanwhile, the contents of α- and δ-granules are released into the immediate environment, further amplifying the original activation signal [23]. As a result, in response to a number of biological mediators, the activated platelets adhere to each other, to leukocytes and endothelial cells, and to components of the sub-endothelial matrix [30].

During extension of platelet plug formation, activated platelets accumulate on top of the initial monolayer of platelets bound to collagen of the sub-endothelium [3]. Expressed receptors on each platelet allow binding of agonists such as ADP, thrombin, and thromboxane A2, which are released from activated platelets [31]. Consequently, more platelets are recruited to the site of injury, thereby consolidating the initial hemostatic plug. Binding of fibrin to aggregated platelets through activated receptor glycoprotein GPIIb/IIIa (integrin αIIbβ3) helps to further stabilize the hemostatic plug [32].

Several proteins are released during platelet aggregation at a damaged blood vessel surface [22]. Some are believed to be responsible for repair of damaged blood vessels and development of new ones. Although precise mechanisms are not well understood, it was suggested that platelets are necessary for formation of new blood vessels [33]. Supporting this are observations of reduced retinal neovascularization in a mouse hypoxia-induced retinal angiogenesis model due to thrombocytopenia or in response to treatment with inhibitors of platelet aggregation [33]. In this context, platelet granules are believed to contain pro- and anti-angiogenic compounds [3435]. Similarly, platelet interactions with cancer cells appear to play a role in the development of metastases and tumor angiogenesis [36]. While cerebrovascular remodeling is known to occur in the newborn in the first few postnatal weeks [37], the roles of platelets in this developmental process are not yet well described.

Platelets may also play a role in newborn’s inflammatory processes and host defense. Neonates are generally believed to be at least partially immunologically incompetent and susceptible to a variety of infections. In this context, it is of interest that platelets have toll-like receptors (TLRs) that directly recognize and interact with a number of microorganisms or their products. Platelets may be responsible for killing microbes directly by phagocytosis, by release of microbicidal agents, or as sentinels communicating information about microbial encounters to cells of the innate immune system [15]. Bacterial infections, found in preterm newborns admitted to the neonatal intensive care unit (NICU), appear similar to infections found in adults with severe neutropenia [38]. This suggests reduced neutrophil functions in these babies. Neonates rely heavily on innate immunity for protection because their adaptive immunity is not yet fully developed [39]. Neutrophils are usually the first cells to be recruited to infection sites. They kill pathogens by various mechanisms including (a) direct phagocytosis and chemical killing by degranulation and (b) by formation of neutrophil extracellular traps (NETs) [40]. Recent studies showed that platelet interactions with neutrophils are important for optimal neutrophil functions [41, 42, 43, 44]. One such aspect of neutrophil function involves their chemotaxis and extravasation to sites of infection. Platelets were observed to act as “pathfinders” guiding neutrophils to infection sites, and platelet inhibition resulted in poor neutrophil chemotaxis [45, 46]. Interaction of platelets with leukocytes may induce inflammation. Understanding the role and mechanisms involved in platelet-leukocyte interactions in the newborn, particularly those born prematurely, could lead to development of more rational approaches to morbidities common to this group.


3. Newborn platelets

Thrombopoietin, a protein regulator of platelet synthesis and homeostasis [18], was detected in the fetal liver as early as the sixth week of gestation [18]. In turn, megakaryocytes, the precursor cells that form and release platelets into circulation, were detected in the liver and circulation at the eighth week [19]. The megakaryocyte numbers were observed to be, at least in part, inversely correlated to gestational age, so that healthy preterm newborns characteristically have higher levels, while levels in healthy full term newborns and adults are similar [47, 48]. Neonatal megakaryocyte progenitor cells are more sensitive and have higher proliferative potential in response to thrombopoietin compared to adult cells, and this sensitivity is even greater in preterm newborns [49]. However, neonatal megakaryocytes, tending to be smaller and with a lower ploidy than adult cells, produce fewer platelets per megakaryocyte [48, 50, 51]. Newborn and adult platelets are ultra-structurally similar [52, 53] and contain comparable membrane receptor glycoproteins (GPs) [54] and thromboxane receptors [55]. However, newborn platelets tend to include more immature forms, with the ability to form fewer pseudopods, fewer developed microtubular structures, and fewer α-granules [53]. Additionally, neonatal platelets have fewer adrenergic receptors [56]. Although they store comparably adult levels of ADP, ATP and serotonin in their dense granules, the overall dense granule release during platelet activation is lower in the newborn [57].

Platelet count is dependent on gestational age, increasing during fetal life, but usually reaches the expected adult range of 150,000 to 450,000/µL [58] from about 22 weeks of gestation [59]. The percentage of reticulated platelets, an indication of newly produced platelets, is higher in the newborn circulation [60], while the mean platelet volume (MPV), a measure of platelet size, tends to be comparable to adults.

Platelet adhesion to, and coverage of, sub-endothelial extracellular matrix is higher in the newborns than in adults [61, 62]. This is in spite of comparable collagen binding or platelet aggregation [61]. The enhanced neonatal platelet adhesion is believed to be mediated by the neonatal plasma von Willebrand factor (vWF) [61], which was reported to include unusually large multimers [63, 64]. Nevertheless, compared to full-term newborns, platelet adhesion tended to be lower in earlier gestational age neonates [62]. In part, these observations could help to explain how hemostatic function is usually maintained in full-term newborns, despite decreased intrinsic platelet activation, and why the preterm neonates are progressively decompensated the earlier their gestational age.

The phospholipid content and baseline exposure of platelet surface phosphatidylserine is comparable in adults and newborns [65, 66]. However, more platelet microparticles are generated and more phosphatidylserine molecules are exposed in the term and preterm platelets when thrombin or calcium ionophores were used as activators [67]. Microparticles or exposed phosphatidylserine is expected to induce a procoagulant state. Yet, the procoagulant activity, especially in the preterm newborn, is generally lower despite the higher levels of generated microparticles and exposed phosphatidylserine [67]. Supplementing neonatal plasma with coagulation factors improves its procoagulant activity so that it becomes comparable to adults. This implies that newborn platelets can often present adequate procoagulant surface, but the apparent poor activity may in part be due to a deficiency of humoral factors [68].

P-selectin expression, as an index of α-granule secretion, was reported lower in newborn platelets compared to adults, especially in the <30 week gestation group [69, 70]. Neonatal dense granule secretion, measured by secreted serotonin, was similar to that in adults when inositol triphosphate, 1-oleoyl-2-acetyl-glycerol, or thrombin was used as an agonist. Collagen-mediated stimulation, however, resulted in lower serotonin secretion in cord blood, although the number of dense granules in adults and neonates was found to be similar [57, 68]. GPIIb/IIIa receptors are expressed early during gestation. Yet, the fraction of active GPIIb/IIIa in neonatal cord and peripheral blood is lower compared to adults [69].

During the first few days of life, platelet activation appears to be less effective, as indicated by flow cytometric studies [69]. However, these activation profiles approach the adult patterns between the tenth and the fourteenth day of life [71]. Proposed explanations for this observed hypo-responsiveness include: relative deficiencies of phospholipid metabolism including thromboxane production, differential regulation of GPIIb/IIIa activation, impaired mobilization of calcium and intracellular signaling, impaired granule secretion, and lower aggregation [72]. These could result from lower intrinsic signal transduction in neonatal platelets [72]. Such effects are further enhanced by lower expression of protease-activated receptor-1 (PAR-1) and PAR-4 [73, 74], which mediate thrombin-dependent platelet activation.

Various components of the hemostatic system in the fetus and neonate are qualitatively and quantitatively different from those in adults [8]. Such differences could be explained either by lower synthesis, higher clearance, or higher consumption [75, 76]. Although the hemostatic system is sometimes thought to be incomplete at birth [72], it nevertheless appears to be adequate for the majority of healthy full-term newborns.


4. Perinatal factors affecting platelet function in the newborn

Acquired platelet dysfunctions are common during the neonatal period especially in preterm newborns. These disorders are usually secondary to perinatal or neonatal conditions such as maternal and neonatal state of health, presence of infections, medications given to mother or to newborn, or interventions for the newborn (Tables 1 and 2). Platelet count and function are usually restored several hours or days after the triggering condition is removed.

FactorEffect on newborn platelet
Hypertension in mother
  • Reduced platelet adhesion and surface coverage [80]

  • Low platelet count [78, 79]

  • Decreased secretion and expression of CD62P, CD63, and CD36 [83]

  • Increased expression of CD62P and CD63 [84]

  • Low platelet and megakaryocyte counts [84]

Magnesium sulfate (prenatal)
  • Reduced ADP-mediated platelet aggregation [97]

Low dose aspirin (prenatal)
  • Reduced platelet aggregation [95]

  • No change in platelet count and aggregation [92, 93]

  • Reduced thromboxane B2 production [94]

  • Prolonged bleeding time and gastrointestinal hemorrhage [104, 105]

  • Reduced prostacyclin and prostaglandin levels [104]

  • Abnormal platelet aggregation up to 4 days after medication [106]

  • Prolonged PFA-100 closure time [108]

Table 1.

Maternal factors affecting platelets in the newborn.

Neonatal factorEffect on newborn platelet
Nitric oxide
  • Abnormal thromboelastogram values [109]

  • Prolonged prothrombin time [109]

  • Prolonged bleeding time [111]

Therapeutic hypothermia
  • Abnormal thromboelastogram values, associated with bleeding [199]

  • Reduced platelet count [123, 200]

  • Prolonged bleeding time and PFA 100 closure time [201]

Asphyxia and RDS
  • Reduced platelet count [113, 118, 120]

  • High MPV and PDW [113, 117]

  • Increased thrombopoietin level [118]

  • Increased thromboxane level [120]

Mechanical ventilation
  • Reduced platelet count [121]

Extracorporeal membrane oxygenation (ECMO)
  • Reduced platelet count [125, 126]

  • Reduced platelet activation [126]

Table 2.

Neonatal factors affecting platelets in the newborn.

RDS, respiratory distress syndrome; MPV, mean platelet volume; PDW, platelet distribution width.

4.1 Prenatal and maternal factors associated with neonatal platelet dysfunction

There are several maternal factors that can impact neonatal platelet function especially during the days preceding delivery. These include maternal hypertensive disorders and prenatal use of aspirin, magnesium sulfate, or antibiotics.

Hypertensive disorders of pregnancy are associated with platelet dysfunctions in the newborn. Pregnancy-induced hypertension (PIH) is a risk factor for early onset thrombocytopenia in the newborn [77]. This is especially true for babies born prior to 36 weeks of gestation [78, 79]. Neonatal platelet counts tend to be inversely correlated to maternal blood pressure [79]. These platelets also exhibited lower adhesion properties [80]. Babies with low birth weight, meconium aspiration, or infections are also at greater risk for thrombocytopenia [81, 82]. Flow cytometric analyses of platelets from premature newborns from preeclamptic mothers demonstrated lower expression of CD62P (P-selectin), CD63 (platelet activation marker), or CD36 (platelet glycoprotein IV (GPIV)) after thrombin stimulation, compared to full-term neonates [83]. However, when compared to other similar preterms, the expression of platelet CD62P and CD63 was relatively higher in newborns from preeclamptic mothers [84]. Additionally, this cohort was also characterized by lower platelet and megakaryocyte counts [84], implying possible disturbances in platelet production [85]. Infants born to hypertensive mothers tend to be hypoxic [86]. Animal model studies suggest that hypoxia tends to favor erythropoiesis over megakaryopoiesis, leading to lower platelet counts [87].

Low dose aspirin (LDA), about 60–100 mg, is sometimes given to pregnant women, who are at risk of developing a hypertensive disorder, or whose fetus has intrauterine growth restriction [88, 89]. Aspirin inhibits cyclooxygenase, which catalyzes the initial steps in conversion of arachidonic acid to prostaglandins and thromboxanes [90]. Thromboxane A2 (TxA2) serves to amplify the signal during platelet activation [91]. Nevertheless, while some reports suggest that prenatal aspirin does not alter cord blood platelet count and aggregation [92] or thromboxane B2 (TxB2) inhibition [93], others challenge this with clear TxB2 differences in newborns of mothers exposed to LDA even several days after the medication was stopped [94]. This apparent contradiction may be resolved by taking into account the actual timing of LDA treatment prior to delivery. It was noted that newborn platelet dysfunction, including reduced collagen-stimulated platelet aggregation, is generally observable if the mother had aspirin within a week of delivery [95]. In this context, aspirin also increases the risk for mucocutaneous bleeding in the newborn, especially if the mother took it within five days of delivery [72, 95].

While aspirin is perhaps the best described with respect to its potential to alter platelet functions, it is not the only drug to do so. Indomethacin, given to the mother as a tocolytic, increased the risk of subsequent neonatal intraventricular hemorrhage (IVH) [96], presumably by affecting cerebral blood flow and by altering platelet and neutrophil functions. Similarly, platelets in newborns, from mothers receiving tocolytic magnesium sulfate, tended to be less effective in forming aggregates in response to ADP-mediated activation, but not so in response to collagen stimulation [97].

4.2 Postnatal and neonatal factors associated with platelet dysfunction in the newborn

Neonatal infections tend to lead to platelet consumption. This is implied by the observed upregulation of thrombopoietin and elevated megakaryocyte progenitor cells in septic newborns [98]. Reduced platelet adhesion was also reported in such neonates [99]. However, enhanced granule secretion and aggregate formation in response to agonists during experimental conditions [100] suggest that these circulating platelets may already be to some extent primed and not in their resting state. Furthermore, neonates born following chorioamnionitis had significantly higher levels of soluble P-selectin and higher CD40L (CD40 ligand, able to bind CD40 protein on antigen presenting cells) on their platelets [101].

Antibiotics are often used to treat infections and sepsis, and some of them could alter hemostatic responses. Prolonged template bleeding and PFA-100 closure times were correlated with duration and dosage of neonatal ampicillin treatment [102, 103].

Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to affect platelet function in adults. Yet, they are sometimes given to newborns as a treatment for patent ductus arteriosus (PDA). Indomethacin is associated with prolonged bleeding time and gastrointestinal bleeding in preterm newborns [104]. These effects tend to last up to 48 h [105], but normal platelet values are restored about the tenth day [106]. Nevertheless, in preterm newborns with intracranial hemorrhage, indomethacin administration for treatment of PDA did not extend the hemorrhage [107]. In contrast, ibuprofen treatment is associated with prolonged PFA-100 closure time, but not with altered bleeding time [108].

Inhaled nitric oxide (NO) is used as a selective pulmonary vasodilator to treat hypoxemic respiratory failure or pulmonary hypertension in newborns (≥34 week gestation) [109]. Inhaled NO prolongs bleeding time in adults [110]. Persistent pulmonary hypertension and treatment with inhaled NO were reported to alter neonatal platelet thromboelastogram (TEG) values [109]. Bleeding time was also prolonged in such babies [111]. These clinical tests, however, returned to normal after about 24 h of stopping therapy. It is of interest that newborns receiving NO therapy did not experience increased risk of intracranial hemorrhage [72]. Nitric oxide is known to inhibit platelet adhesion and aggregation by inhibiting GPIIb/IIIa activation [110]. A reduction in expressed P-selectin and activated GPIIb/IIIa on collagen-stimulated platelets was reported after NO treatment in adults and newborns [112].

Term newborns who were small for gestational age tended to have lower platelet counts but higher mean platelet volumes (MPVs) [113, 114]. A similar pattern was also observed in asphyxiated term newborns [113]. MPV is a measure of average platelet size [115] and may serve as a marker of platelet production, consumption, or severity of some disorder of bone marrow, thrombosis, or infection [116, 117]. For example, MPV was elevated in preterm newborns with respiratory distress [117], suggesting potential issues in platelet production, consumption, or both. Asphyxia is associated with upregulation of thrombopoietin concentration, which in turn is negatively correlated to platelet count up to the 7th day of life [118]. Thrombocytopenia, however, when associated with perinatal asphyxia, does not tend to resolve until about the 19th to 21st day of life [119]. Increased thromboxane levels in asphyxiated newborns [120] suggest platelet activation, and possibly consumption, as an explanation for the observed thrombocytopenia. Hypoxia leads to preferential upregulation of erythropoiesis over megakaryopoiesis [87, 114], consistent with elevated thrombopoietin observed [118].

Mechanical ventilation is generally used to resuscitate hypoxic or asphyxiated newborns. It was reported that mechanical ventilation led to reduced platelet counts in newborns with respiratory distress, or in rabbit models, regardless of the oxygen concentration used [121]. However, using newborn piglet models of hypoxia, it was found that various platelet indices were affected particularly by high oxygen level used [122]. Resuscitation with 100% oxygen led to enhanced collagen-stimulated platelet aggregation, while using 18–21% oxygen did not do so [122].

To prevent permanent brain damage following perinatal asphyxia, the newborns are sometimes treated with therapeutic hypothermia. The hypothermia treatment, in turn, led to decreased platelet counts, but had an overall protective effect by reducing risk of cerebral hemorrhage [123] and restoring other hemostatic parameters [124]. Similarly, extracorporeal membrane oxygenation (ECMO) is used to rescue term newborns with persistent pulmonary hypertension, asphyxia, or congenital diaphragmatic hernia [125]. Platelet counts and rates of activation were reduced during ECMO therapy, and were not fully restored with transfusion, until several hours post-ECMO [125, 126].


5. Platelets and sepsis

Sepsis is a complex syndrome characterized by disordered immune, endocrine, and metabolic responses to infection [127]. The exaggerated responses can lead to multi-organ failure (MOF), shock, and death [127]. Sepsis is generally considered if a documented or suspected infection is present with at least one additional finding (e.g., fever/hypothermia, elevated heart rate, and leukocytosis/leukopenia). In contrast to infection, however, sepsis is defined by additional evidence of organ dysfunction and a dysregulated host immune response [127], its key features. Notably, interactions between the innate immune system and the hemostatic system, including platelets and coagulation factors, were identified as principal steps in the pathogenesis of sepsis. Progressive thrombocytopenia and coagulopathy are strong negative prognostic findings in severe sepsis and have recently been included in the updated definition of the disease [127]. Platelets are able to release cytokines, recruit leukocytes, interact with bacteria and the endothelium, and contribute to formation of microthrombi [128]. These processes are adaptive and protective in the context of a localized infection, but may become dysregulated and “maladaptive” during sepsis, contributing to organ damage [129]. A low platelet count is a well-known biomarker for disease severity. More recently, attention has been focused on the active role of platelets in the pathogenesis of multi-organ failure.

The correlation between thrombocytopenia and sepsis is well documented [130]. Platelet count below <50,000/μL is a strong negative prognostic marker in patients with sepsis and is thought to result from platelet activation and consumption [131, 132]. A number of platelet function markers were proposed as biomarkers for sepsis correlating with its severity [133] (Table 3).

Impaired platelet functionMOF, mortality[132, 133]
Impaired platelet aggregationALI[133]
Platelet-neutrophil aggregatesSepsis progression[132, 133]
Immature platelet fractionMOF[133]

Table 3.

Platelet-related biomarkers of sepsis severity in human studies.

MOF, multi-organ failure; ALI, acute lung injury; TPO, thrombopoietin.

Moreover, platelets interact with neutrophils in the formation of NETs (neutrophil extracellular traps) resulting in the trapping and killing of pathogens [133]. They also play a central role in driving and modulating host inflammatory and immune responses, influencing directly the function of endothelial cells, neutrophils, and lymphocytes [134]. Platelets are the most numerous blood cells with immune function, able to interact with bacteria in several ways: (1) direct interaction between platelet glycoproteins and bacterial surface proteins, as occurs between GPIb and S. sanguis SrpA [134]; (2) indirect interactions, such as the interaction of platelet αIIbβ3 with fibrinogen to which the clumping factors of S. aureus bind [134]; and (3) upon activation, platelets release a series of factors which can modulate the immune response or have direct microbicidal effects. For example, released thrombin-induced platelet microbicidal protein (tPMP-1) can directly lyse bacteria, like S. aureus [134].

5.1 Conclusions

In addition to hemostasis, platelets actively participate in the innate immune defense system. Participating in the recognition of pathogens, signal transduction, or the release of cytokines/chemokines, they reveal a functional similarity with leucocytes in sepsis and septic shock. There is abundant evidence that platelets can influence key host responses to sepsis. Further studies are needed to address the effects of platelet transfusion or inhibition toward sepsis prevention and treatment particularly in the newborn.


6. Platelets in neonates with extracorporeal membrane oxygenation

Extracorporeal membrane oxygenators are used to provide gas exchange in severe respiratory failure employing venovenous (VV) circuits or, increasingly, if associated with concurrent cardiac failure, veno-arterial (VA) circuits, while waiting for organ recovery to occur. Support by cardiopulmonary bypass (CPB) systems decreased the morbidity and mortality of children, especially those who require surgery for life-threatening anatomical heart defects [135, 136]. ECMO contributed to decreased mortality for children with severe cardiac or respiratory failure [137, 138]. While annually thousands of neonates are helped by ECMO support, thromboembolic complications also frequently occur [139]. Nevertheless, for many neonatal patients, survival is made possible only because of ECMO support [136]. ECMO is used to treat a variety of conditions in neonatal patients, including respiratory and cardiac failure as a result of persistent pulmonary hypertension (PPHN), congenital diaphragmatic hernia (CDH), meconium aspiration syndrome (MAS), respiratory distress syndrome (RDS), pneumonia, severe air-leak syndromes, or sepsis [140].

Both bleeding and clotting complications can occur during ECMO support, often coexist in the same patient, and are associated with significant morbidity and mortality [141]. Moreover, patients requiring ECMO are critically ill, thus making it difficult to distinguish the relative contributions of the underlying pathology from that of the ECMO circuit as such. Rates of reported ECMO-associated venous thromboembolism (VTE) in general population, ranging from 18 to 85% in various centers, may be at least partly dependent on anticoagulation regimens [141]. Severe hemorrhage is reported in nearly 40% and intracranial hemorrhage in 16–21% of patients [142, 143]. At the same time, there is broad variation in practice, without clear consensus, on the administration and monitoring of anticoagulation during ECMO, or the management of ECMO-related hemorrhage and VTE [144].

Activation of the coagulation system is initiated by the exposure of blood to foreign synthetic surfaces and by shear stresses of the circuit, especially from device pumps. The shift to a pro-coagulant state appears to be mediated primarily by thrombin, while an excessive fibrinolytic tendency is mediated by plasmin, resulting in a consumption of clotting factors, impaired platelet function, thrombocytopenia, and fibrinolysis [145]. Initial fibrinogen deposition and subsequent activation of coagulation and complement factors allow platelets and leukocytes to adhere to oxygenator surfaces further enhancing thrombin generation. Such changes contribute to higher rates of thrombosis in these patients [145]. Meanwhile, several of a series of processes contribute to higher bleeding rates. (a) Primary hemostasis is impaired because of platelet dysfunction and loss of key adhesive molecules. (b) Shear stress causes the development of an acquired von Willebrand defect. (c) Widespread fibrin deposits on surfaces trigger an enhanced fibrinolytic response. (d) Administration of systemic anticoagulation, required to maintain circuit patency, raises bleeding risks [146].

Balancing the relative risks of bleeding and thrombosis can be difficult. Factors related to patient’s illness, the extracorporeal support, and the interplay between pro-inflammatory and anti-inflammatory processes vary among patients.

6.1 Platelet dysfunction during ECMO

If the ECMO circuit is primed only with crystalloid or RBCs and plasma, then dilutional coagulopathy and dilutional thrombocytopenia develop as the ECMO is initiated. Dilutional coagulopathy is generally not severe, but will complement the systemic anticoagulation. Dilutional thrombocytopenia, however, may further aggravate any preexisting thrombocytopenia or platelet dysfunction, frequently present in premature neonates. Accurate assessment of platelet function under these circumstances can be difficult, further complicating evaluation of patient’s bleeding or thrombotic potential. Impairment of platelets can occur as early as 15 min after starting ECMO and last until it is discontinued [125].

Platelets adhere to the protein-coated monolayer of the ECMO circuit surfaces and interact with activated components of the coagulation and complement systems [147]. Elevated shear flow from the ECMO circuit causes some platelet receptor shedding. Of particular interest are the losses of key platelet adhesion glycoproteins GPI and GPVI, and the associated reduction of high molecular weight vWF multimers. GPI serves as a receptor for vWF and GPVI as a receptor for collagen [126]. Adhesive proteins, vWF, and fibrinogen assist platelets to bind to damaged vessel wall surface and to other platelets [148]. As platelet thrombus is being formed, the prothrombinase enzyme complex assembles on the activated platelet surfaces to produce thrombin. In turn, thrombin cleaves fibrinogen to form fibrin, which spontaneously polymerizes to form the fibrin meshwork, which further strengthens the thrombus [149]. Consequently, shedding of GPI and loss of high molecular weight vWF lead to dysfunctional platelet responses to vascular injury. This persists despite platelet transfusion and throughout the period of ECMO use [126]. Subsequently, lower levels of platelet aggregation are observed by light aggregometry using various agonists including ADP, ristocetin, collagen, or epinephrine [150]. Such decreased potential for platelet aggregation may lead to increased bleeding risk particularly when combined with the effects of anticoagulants or antiplatelet agents. Flow cytometry of blood, from those receiving ECMO support, showed severely reduced membrane-bound P-selectin (CD62P) and CD63, both of which modulate platelet spreading [151].

Despite reduced aggregation and lower expression of key platelet adhesion and structural molecules, there is a time-dependent platelet activation marked by increased levels of circulating matrix metalloproteinase-2 (MMP-2) and soluble P-selectin [126]. This is not associated with significant activation of the endothelium [126], but may be due to the release of platelet granules [152]. Furthermore, this time-dependent platelet activation is also accompanied by platelet receptor shedding and the release of platelet microparticles (PMPs) [153]. These are small cell-derived particles, typically 0.1–1 μm in size, that are produced from activated platelets in situations of shear stress [154]. While these PMPs can present a prothrombotic surface, it is not clear whether they are a major contributor to the prothrombotic phenotype or to the pathogenesis of ECMO-associated coagulopathy [153].

6.2 Platelet counts during ECMO

Thrombocytopenia is common in critically ill patients. A constant shear force, caused by the ECMO pump, is implicated in acquired platelet dysfunctions. Appropriate anticoagulation is difficult to achieve during ECMO since severe thrombocytopenia of <50,000/μL may be present even prior to ECMO. This situation increases the practice of platelet transfusions [155]. Minimal target platelet counts vary from 25,000 to 100,000/μL between hospitals. However, if bleeding occurs or is expected, then target platelet counts are increased to 150,000/μL or higher, particularly if platelet dysfunction is suspected. As in any setting of thrombocytopenia, it is important to try and identify the cause and treat appropriately [156, 157]. Bleeding in critically ill patients with a platelet count of 30,000/μL is believed to be associated with additional disturbances of hemostasis [158]. Platelet transfusion is recommended in bleeding patients with either primary or secondary platelet abnormalities regardless of platelet counts [158]. Required thresholds for prophylactic platelet transfusions, however, are generally at platelet levels above 20,000/μL, given the requirements of invasive procedures and potential bleeding risk [158]. Many centers describe targeting a platelet count of >100,000/µL during an ECMO [159]. Research to support this practice, however, is lacking and urgently needed.

6.3 Anticoagulation during ECMO

Unfractionated heparin is the most widely used anticoagulant during ECMO [160]. Heparin levels tend to be monitored primarily indirectly by activated clotting time (ACT) [159]. While there are a number of devices that promise to describe certain characteristics of platelet function, it is not yet clear to what extent the data produced by them actually reflect the physiological platelet interactions and roles. Viscoelastic tests using rotational thromboelastometry (ROTEM) assess whole blood coagulation, and thus provide information on the dynamics of clot development, stabilization, and dissolution. Several reports suggest that ROTEM-guided coagulation management could reduce bleeding episodes in ECMO patients [160, 161]. Similarly, whole blood platelet aggregometry using the Multiplate (Roche Diagnostics, Munich, Germany) demonstrated decreased platelet aggregation in ECMO patients [161].

Other intravenous anticoagulants, such as bivalirudin and argatroban, are used increasingly, particularly if heparin-induced thrombocytopenia (HIT), heparin resistance, or allergy is suspected [162, 163]. At present, there is no clear consensus on administration and monitoring of anticoagulation during ECMO or on management of ECMO-related hemorrhage and VTE [164]. The current aim of anticoagulation is to reduce thrombin generation. This, however, increases the risk of hemorrhage. The ideal therapeutic agent, which would reduce thrombotic risk without increasing the risk of bleeding, remains elusive.

6.4 Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is an immune-mediated coagulation side effect of heparin therapy characterized by a prothrombotic state mediated by platelets, leukocytes, and antibodies against complexes of platelet factor 4 (PF4) with long chain heparins [165]. Rapid platelet consumption leads to thrombocytopenia. HIT was considered to be very rare in the pediatric population. However, more recent reports indicate that it occurs in children receiving unfractionated heparin therapy with an incidence similar to that seen in adults [166]. The highest incidence of pediatric HIT was found in pediatric intensive care units supporting patients following cardiac surgery [167].

At least 70 cases of reported HIT were documented in pediatric patients [168], with the majority occurring during care following cardiac surgery. HIT in children was reported to occur in all age groups, but with a bimodal distribution. The higher incidences occur a) early in life, between 0–2, and b) during puberty, between 11–17 years of age [168, 169]. The balance between the risk of procoagulant and thromboembolic events on one hand and the risk of severe, sometimes fatal, bleeding on the other hand can be very challenging in ECMO patients with HIT. Pollak et al. reported a case of HIT with evidence of small vessel arterial thrombosis in a 5-day-old newborn receiving ECMO for congenital diaphragmatic hernia. It was assumed that the leading cause of death in this patient was massive disseminated intravascular coagulation. In this case, however, it is more likely that repeated platelet transfusions proved fatal and, retrospectively speaking, should have been avoided [170]. Although HIT is a recognizable and treatable complication, its relative infrequency increases the risk for delayed diagnosis leading to significant morbidity.

Diagnostic studies for HIT tend to be unreliable. Therefore, early intervention using alternative anticoagulants is a crucial step when HIT is suspected. This can hopefully lead to improved outcomes in these patients. Treatment of confirmed or suspected HIT in patients on ECMO includes removing unfractionated heparin, and possibly the entire ECMO circuit. Certain modern ECMO circuit components are heparin bonded in an effort to reduce immune reactivity to foreign surfaces [171, 172, 173]. If platelet recovery does not occur after withdrawal of heparin, it is possible that ongoing exposure to heparin bonding may be a factor [173]. Options for alternative anticoagulation if HIT is suspected include direct thrombin inhibitors (argatroban and bivalirudin) as well as short heparinoids (fondaparinux and danaparoid) [162, 174].

6.5 Conclusions

The predominant challenge for the clinician caring for a patient on ECMO is making an informed assessment of bleeding and clotting risks. The goal is to minimize bleeding and transfusion requirements while avoiding formation of micro or macro thrombi either in the circuit or within the patient’s cardiovascular system [175]. Assessment of the patient’s hemostasis includes consideration of the pathophysiology, type and severity of organ failure, and extent of tissue trauma during cannulation. A holistic approach to hemostatic management is needed to balance all these factors. ROTEM and whole blood platelet aggregometry provide rapid information on whole blood coagulation, and may be helpful in providing blood product support, factor replacement, anti-coagulation therapy and anti-fibrinolytics. Further research using ROTEM and whole blood platelet aggregometry in ECMO patients is needed to demonstrate efficacy in support of real-time hemostatic management in this cohort.


7. Platelet transfusions in neonates

Transfusion of blood products in neonates is not an uncommon practice in neonatal intensive care units. Extremely premature neonates (<28 week gestation) or extremely low birth weight (ELBW) infants (<1000 g) receive at least one packed red blood cell (pRBC) transfusion per hospital admission [176]. Platelet transfusions are also quite prevalent in ELBW infants, occurring in up to 90% of those weighing less than 750 g [177]. Unfortunately, while platelet transfusions for thrombocytopenia may be helpful, they are not without risk. Further, because the guidelines for transfusion thresholds in neonates are not based on a well-developed body of evidence, there is considerable variability in circumstances for such transfusions, and in particular clinical scenarios triggering them.

Thrombocytopenia is defined by a platelet count of less than 150,000/μL, and is further sub-classified as mild (100,000–149,000/µL), moderate (50,000–99,000/µL), or severe (<50,000/μL) [178]. The reference values for very low birth weight (VLBW) babies (<1500 g), however, remain controversial [179]. Thrombocytopenia affects 18–35% of all neonates in the neonatal intensive care unit [180, 181] and up to 73% of ELBW infants [182]. While clinical significance of platelet counts between 100,000 and 150,000/µL is debatable, it is well known that platelet counts below 20,000/µL are associated with increased risk of hemorrhage, at least in the adult population [183]. The relationship between thrombocytopenia and hemorrhage, however, remains one of the associations. It is not clear that neonatal thrombocytopenia directly causes hemorrhagic events [184].

Thrombocytopenia may be described by time of onset, where early onset (occurring in the first 72 h of life) is distinguished from late onset (occurring after the first 72 h of life) [179, 184]. In the premature population, the early onset thrombocytopenia is most often mild to moderate, develops gradually, and tends to be related to causes of chronic fetal hypoxia, as seen with intra-uterine growth restriction (IUGR), pregnancy-induced hypertension (PIH), hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome, or preeclampsia [185]. In term neonates, however, platelet destruction tends to be antibody-mediated [184]. In contrast to early onset, late onset thrombocytopenia tends to be more severe, more acute, and most frequently associated with infections (NEC, sepsis, and viral infections) [184].

7.1 Indications for platelet transfusion

Due to limited understanding of neonatal platelet functions, transfusion practice in the newborn is generally extrapolated from what is recognized as beneficial within the pediatric and adult populations. However, neonates are vulnerable to particular illnesses with varying underlying disease processes. Moreover, they tend to have developmental differences in regulation of primary hemostasis [178]. Nevertheless, platelet transfusions are typically given in two distinct clinical scenarios: (a) acutely, as a life-saving procedure and (b) prophylactically, under the presumption that they diminish the risk for hemorrhage. Surprisingly, an overwhelming majority of neonatal transfusions are done prophylactically, accounting for 98% of platelet transfusions [59]. Yet, it is not clear that this practice is beneficial. Prophylactic platelet transfusion in clinically stable neonates with no active bleeding remains controversial at best [186], consistent with the wide range of national and international clinical practices by neonatologists [177]. In this context, the severity of thrombocytopenia does not correlate with increased risk of intraventricular hemorrhage (IVH), and platelet transfusion for mild to moderate thrombocytopenia does not appear to prevent or reduce the incidence of intracranial hemorrhage [183, 187].

Although adequate quantities of platelets are necessary for hemostasis, increased risk of hemorrhage appears to be dependent on factors other than thrombocytopenia alone. Additional relevant platelet parameters include functional competency, immature platelet fraction, and developmental differences in neonatal thrombopoiesis [49, 188, 189]. Underlying clinical conditions associated with increased risk of hemorrhage include: preterm premature rupture of membranes, low birth weight, sepsis, shock, pulmonary hypertension, respiratory distress, NEC, and premature gestational age [182, 190, 191, 192]. Thus, recommendations to transfuse platelets should not be solely based on thrombocytopenia, but also on the presence of such other contributory factors [178, 190]. In spite of such considerations, it appears that management of thrombocytopenia in the newborn still lacks adequately rigorous scientific basis [179].

7.2 Clinical guidelines for platelet transfusion in neonates

In the United States, there are currently no national guidelines for neonatal platelet transfusion and only two published randomized controlled trials assessing prophylactic transfusions [183, 193]. Most countries recommend therapeutic transfusion in actively bleeding neonates when platelets fall below 50,000/μL. However, there is no agreement regarding prophylactic transfusions when platelets are anywhere between 20,000 and 90,000/μL [184, 194, 195]. A wide range of thrombocytopenia thresholds are employed, tending to be markedly higher in the United States, between 50,000 and 149,000/µL [187, 196, 197]. Nonetheless, such trends are based on clinical experience and judgment, rather than on reliable and consistent data.

7.3 Adverse outcomes of platelet transfusions

A growing number of adverse effects of platelet transfusions are being documented, including but not limited to increased risk of infection, transfusion-related injuries in various organs, alloimmunization, hemolytic reactions, febrile reactions, allergic reactions, anaphylaxis, and NEC [177, 185]. Randomized controlled trials comparing thresholds for platelet transfusion in thrombocytopenic neonates concluded that the frequency of IVH is not reduced by more aggressive thresholds [183]. Additionally, platelet transfusions, themselves, are implicated in increased mortality, linking the number of transfusions with death rate [198]. This was further supported by a recent large, multicenter, randomized clinical trial suggesting that significant hemorrhage and death could be prevented by lowering thrombocytopenia transfusion thresholds from 50,000 to 25,000/μL [193].


8. Conclusions

Platelets are best known for their role in hemostasis. But beyond forming a platelet plug, they are also important in several processes such as recognition and elimination of invading microorganisms, inflammation and interaction with leukocytes, wound healing and tissue repair, angiogenesis, and even tumor growth. These are emerging areas of investigation and there is little to no information on the roles of platelets in such processes in the newborn. Although current understanding suggests that newborn platelets may be somewhat different from adult platelets, they nonetheless protect the healthy newborn adequately. Certain perinatal factors were identified to affect platelet counts and function, but the platelet dysfunctions induced by them are acquired and transitory in nature. Premature neonates are likely at greatest risk for reduced platelet counts and functions, and by extension, at greatest risk of hemorrhage, particularly if prematurity is in combination with antenatal infections or postnatal respiratory disorders. There is, however, still a lot that is not known about platelets in the newborn. Such information is critical to improving the standard of care, intervention, and therapy.



This work was supported in part by NIH grant R01 NR011209-08.


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1. Harrison P. Platelet function analysis. Blood Reviews. 2005;19:111-123. DOI: 10.1016/j.blre.2004.05.002
  2. 2. Leslie M. Beyond clotting: The powers of platelets. Science. 2010;328(5978):562-564. DOI: 10.1126/science.328.5978.562
  3. 3. Storti F, Kempen THS, Vosse FN. A continuum model for platelet plug formation and growth. International Journal of Numerical Methods in Biomedical Engineering. 2014;30(6):634-658. DOI: 10.1002/cnm.2623
  4. 4. Hou Y, Carrim N, Wang Y, Gallant RC, Marshall A, Ni H. Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. Journal of Biomedical Research. 2015;29(6):437-444. DOI: 10.7555/JBR.29.20150121
  5. 5. Muthard RW, Welsh JD, Brass LF, Diamond SL. Fibrin, γ’-fibrinogen, and trans-clot pressure gradient control hemostatic clot growth during human blood flow over a collagen/tissue factor wound. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(3):645-654. DOI: 10.1161/ATVBAHA.114.305054
  6. 6. Colace T, Muthard R, Diamond SL. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: Role of thrombin with and without fibrin. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32(6):1466-1476. DOI: 10.1161/ATVBAHA.112.249789
  7. 7. Manco-Johnson MJ. Development of hemostasis in the fetus and neonate. Thrombosis Research. 2007;119:S4-S5. DOI: 10.1016/s0049-3848(07)70004-x
  8. 8. Haley KM, Recht M, McCarty OJT. Neonatal platelets: Mediators of primary hemostasis in the developing hemostatic system. Pediatric Research. 2014;76(3):230-237. DOI: 10.1038/pr.2014.87
  9. 9. Boulaftali Y, Hess PR, Getz TM, Cholka A, Stolla M, Mackman N, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. Journal of Clinical Investigation. 2013;123(2):908-916. DOI: 10.1172/jci65154
  10. 10. Kollmann TR, Kampmann B, Mazmanian SK, Marchant A, Levy O. Protecting the newborn and young infant from infectious diseases: Lessons from immune ontogeny. Immunity. 2017;46(3):350-363. DOI: 10.1016/j.immuni.2017.03.009
  11. 11. Hallevi H, Walker KC, Kasam M, Bornstein N, Grotta JC, Savitz SI. Inflammatory response to intraventricular hemorrhage: Time course, magnitude and effect of t-PA. Journal of the Neurological Sciences. 2012;315(1-2):93-95. DOI: 10.1016/j.jns.2011.11.019
  12. 12. Dani C, Cecchi A, Bertini G. Role of oxidative stress as physiopathologic factor in the preterm infant. Minerva Pediatrica. 2004;56(4):381-394
  13. 13. Nurden AT. Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis. 2011;105(99):S13-S33. DOI: 10.1160/THS10-11-0720
  14. 14. Kaushansky K. Historical review: Megakaryopoiesis and thrombopoiesis. Blood. 2008;111(3):981-986. DOI: 10.1182/blood-2007-05-088500
  15. 15. Andres O, Schulze H, Speer CP. Platelets in neonates: Central mediators in haemostasis, antimicrobial defence and inflammation. Thrombosis and Haemostasis. 2015;113(1):3-12. DOI: 10.1160/TH14-05-0476
  16. 16. Liu Z-J, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, et al. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood. 2014;123(22):3381-3389. DOI: 10.1182/blood-2013-06-508200
  17. 17. Watts TL, Murray NA, Roberts IAG. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatric Research. 1999;46(1):28-32. DOI: 10.1203/00006450-199907000-00005
  18. 18. Murray NA, Watts TL, Roberts IA. Thrombopoietin in the fetus and neonate. Early Human Development. 2000;59(1):1-12. DOI: 10.1016/S0378-3782(00)00078-5
  19. 19. Del Vecchio A, Motta M, Romagnoli C. Neonatal platelet function. Clinics in Perinatology. 2015;42(3):625-638. DOI: 10.1016/j.clp.2015.04.015
  20. 20. Brass L. Understanding and evaluating platelet function. Hematology. American Society of Hematology. Education Program. 2010;2010(1):387-396. DOI: 10.1182/asheducation-2010.1.387
  21. 21. Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(10):5556-5561. DOI: 10.1073/pnas.95.10.5556
  22. 22. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Reviews. 2015;29(3):153-162. DOI: 10.1016/j.blre.2014.10.003
  23. 23. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: Linking hemostasis and inflammation. Blood Reviews. 2007;21(2):99-111. DOI: 10.1016/j.blre.2006.06.001
  24. 24. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circulation Research. 2013;112(11):1506-1519. DOI: 10.1161/circresaha.113.300512
  25. 25. Ogedegbe HO. An overview of hemostasis. Laboratory Medicine. 2002;33(12):948-953. DOI: 10.1092/QWJQLR8ELGL6X32H
  26. 26. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thrombosis and Haemostasis. 2002;88(2):186-193. DOI: 10.1055/s-0037-1613209
  27. 27. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: Mechanisms of bacterial-induced platelet activation. Journal of Thrombosis and Haemostasis. 2011;9(6):1097-1107. DOI: 10.1111/j.1538-7836.2011.04264.x
  28. 28. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Progress in Lipid Research. 2003;42(5):423-438. DOI: 10.1016/S0163-7827(03)00025-0
  29. 29. George JN. Platelets. Lancet. 2000;355(9214):1531-1539. DOI: 10.1016/S0140-6736(00)02175-9
  30. 30. Kuhle S, Male C, Mitchell L. Developmental hemostasis: Pro- and anticoagulant systems during childhood. Seminars in Thrombosis and Hemostasis. 2003;29(4):329-337. DOI: 10.1055/s-2003-42584
  31. 31. Brass LF. Thrombin and platelet activation. Chest. 2003;124(3 Suppl):18S-25S. DOI: 10.1378/chest.124.3_suppl.18S
  32. 32. Mann K, Brummel-Ziedins K. Normal Coagulation: DTIC Document.2014
  33. 33. Rhee J-S, Black M, Schubert U, Fischer S, Morgenstern E, Hammes H-P, et al. The functional role of blood platelet components in angiogenesis. Thrombosis and Haemostasis. 2004;92(2):394-402. DOI: 10.1160/TH03-04-0213
  34. 34. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets. 2015;26(3):199-211. DOI: 10.3109/09537104.2014.909022
  35. 35. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood. 2008;111(3):1227-1233. DOI: 10.1182/blood-2007-09-113837
  36. 36. Bambace NM, Holmes CE. The platelet contribution to cancer progression. Journal of Thrombosis and Haemostasis. 2011;9(2):237-249. DOI: 10.1111/j.1538-7836.2010.04131.x
  37. 37. Lacoste B, Gu C. Control of cerebrovascular patterning by neural activity during postnatal development. Mechanisms of Development. 2015;138(Pt 1):43-49. DOI: 10.1016/j.mod.2015.06.003
  38. 38. Carr R. Neutrophil production and function in newborn infants. British Journal of Haematology. 2000;110(1):18-28. DOI: 10.1046/j.1365-2141.2000.01992.x
  39. 39. Karenberg K, Hudalla H, Frommhold D. Leukocyte recruitment in preterm and term infants. Molecular and Cellular Pediatrics. 2016;3(1):35. DOI: 10.1186/s40348-016-0063-5
  40. 40. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nature Reviews Immunology. 2013;13(3):159-175. DOI: 10.1038/nri3399
  41. 41. Mauler M, Seyfert J, Haenel D, Seeba H, Guenther J, Stallmann D, et al. Platelet-neutrophil complex formation—A detailed in vitro analysis of murine and human blood samples. Journal of Leukocyte Biology. 2016;99(5):781-789. DOI: 10.1189/jlb.3TA0315-082R
  42. 42. Etulain J, Negrotto S, Carestia A, Pozner RG, Romaniuk MA, D'Atri LP, et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thrombosis and Haemostasis. 2012;107(1):99-110. DOI: 10.1160/th11-06-0443
  43. 43. Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Kansas GS, Snapp KR. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation. 1998;98(9):873-882. DOI: 10.1161/01.cir.98.9.873
  44. 44. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, Figler R, et al. P-selectin–mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30(12):2392-2399. DOI: 10.1161/ATVBAHA.110.211615
  45. 45. Zuchtriegel G, Uhl B, Puhr-Westerheide D, Pörnbacher M, Lauber K, Krombach F, et al. Platelets guide leukocytes to their sites of extravasation. PLoS Biology. 2016;14(5):e1002459. DOI: 10.1371/journal.pbio.1002459
  46. 46. Kornerup KN, Salmon GP, Pitchford SC, Liu WL, Page CP. Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. Journal of Applied Physiology. 2010;109(3):758-767. DOI: 10.1152/japplphysiol.01086.2009
  47. 47. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatric Research. 1998;43(1):148-151. DOI: 10.1203/00006450-199801000-00023
  48. 48. Sola MC, Juul SE, Meng YG, Garg S, Sims P, Calhoun DA, et al. Thrombopoietin (Tpo) in the fetus and neonate. Early Human Development. 1999;53(3):239-250. DOI: 10.1016/S0378-3782(98)00077-2
  49. 49. Ferrer-Marin F, Stanworth S, Josephson C, Sola-Visner M. Distinct differences in platelet production and function between neonates and adults: Implications for platelet transfusion practice. Transfusion. 2013;53(11):2814-2821. DOI: 10.1111/trf.12343
  50. 50. Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors (BFU-MK and CFU-MK) in term and pre-term neonates. British Journal of Haematology. 1995;89(1):41-46. DOI: 10.1111/j.1365-2141.1995.tb08913.x
  51. 51. Clapp DW, Baley JE, Gerson SL. Gestational age-dependent changes in circulating hematopoietic stem cells in newborn infants. The Journal of Laboratory and Clinical Medicine. 1989;113(4):422-427
  52. 52. Saving K, Aldag J, Jennings D, Caughey B, Regan M, Powers W. Electron-microscopic characterization of neonatal platelet ultrastructure—Effects of sampling techniques. Thrombosis Research. 1991;61(1):65-80. DOI: 10.1016/0049-3848(91)90169-w
  53. 53. Saving KL, Jennings DE, Aldag JC, Caughey RC. Platelet ultrastructure of high-risk premature-infants. Thrombosis Research. 1994;73(6):371-384. DOI: 10.1016/0049-3848(94)90039-6
  54. 54. Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier JL. Determination of platelet antigens and glycoproteins in the human fetus. Blood. 1986;68(2):488-492
  55. 55. Israels SJ, Odaibo FS, Robertson C, McMillan EM, McNicol A. Deficient thromboxane synthesis and response in platelets from premature infants. Pediatric Research. 1997;41(2):218-223. DOI: 10.1203/00006450-199702000-00011
  56. 56. Corby DG, O'Barr TP. Decreased alpha-adrenergic receptors in newborn platelets: Cause of abnormal response to epinephrine. Developmental Pharmacology and Therapeutics. 1981;2(4):215-225
  57. 57. Mankin P, Maragos J, Akhand M, Saving KL. Imparied platelet—Dense granule release in neonates. Journal of Pediatric Hematology/Oncology. 2000;22(2):143-147. DOI: 10.1097/00043426-200003000-00012
  58. 58. Wasiluk A, Mantur M, Kemona-Chetnik I, Szczepanski M, Warda J, Bochenko-Luczynska J. Does prematurity affect thrombocytopoiesis? Platelets. 2007;18(6):424-427. DOI: 10.1080/09537100701206816
  59. 59. Sola-Visner M. Platelets in the neonatal period: Developmental differences in platelet production, function, and hemostasis and the potential impact of therapies. Hematology. American Society of Hematology. Education Program. 2012;2012:506-511. DOI: 10.1182/asheducation-2012.1.506
  60. 60. Saxonhouse MA, Sola MC, Pastos KM, Ignatz ME, Hutson AD, Christensen RD, et al. Reticulated platelet percentages in term and preterm neonates. Journal of Pediatric Hematology/Oncology. 2004;26(12):797-802
  61. 61. Shenkman B, Linder N, Savion N, Tamarin I, Dardik R, Kennet G, et al. Increased neonatal platelet deposition on subendothelium under flow conditions: The role of plasma von Willebrand factor. Pediatric Research. 1999;45(2):270-275. DOI: 10.1203/00006450-199902000-00019
  62. 62. Linder N, Shenkman B, Levin E, Sirota L, Vishne T, Tamarin I, et al. Deposition of whole blood platelets on extracellular matrix under flow conditions in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2002;86(2):F127-F130. DOI: 10.1136/fn.86.2.F127
  63. 63. Katz JA, Moake JL, McPherson PD, Weinstein MJ, Moise KJ, Carpenter RJ, et al. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood. 1989;73(7):1851-1858
  64. 64. Weinstein MJ, Blanchard R, Moake JL, And EV, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology. 1989;72(1):68-72. DOI: 10.1111/j.1365-2141.1989.tb07654.x
  65. 65. Bernhard H, Rosenkranz A, Novak M, Leschnik B, Petritsch M, Rehak T, et al. No differences in support of thrombin generation by neonatal or adult platelets. Hämostaseologie. 2009;29(Suppl 1):S94-S97
  66. 66. Bernhard H, Rosenkranz A, Petritsch M, Kofeler H, Rehak T, Novak M, et al. Phospholipid content, expression and support of thrombin generation of neonatal platelets. Acta Paediatrica. 2009;98(2):251-255. DOI: 10.1111/j.1651-2227.2008.01075.x
  67. 67. Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: Differences between neonates and adults. Thrombosis and Haemostasis. 2000;84(4):689-694. DOI: 10.1055/s-0037-1614088
  68. 68. Israels SJ, Daniels M, McMillan EM. Deficient collagen-induced activation in the newborn platelet. Pediatric Research. 1990;27(4Pt 1):337-343. DOI: 10.1203/00006450-199004000-00004
  69. 69. Sitaru AG, Holzhauer S, Speer CP, Singer D, Obergfell A, Walter U, et al. Neonatal platelets from cord blood and peripheral blood. Platelets. 2005;16(3-4):203-210. DOI: 10.1080/09537100400016862
  70. 70. Rajasekhar D, Barnard MR, Bednarek FJ, Michelson AD. Platelet hyporeactivity in very low birth weight neonates. Thrombosis and Haemostasis. 1997;77(5):1002-1007. DOI: 10.1055/s-0038-1656093
  71. 71. Bednarek FJ, Bean S, Barnard MR, Frelinger AL, Michelson AD. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thrombosis Research. 2009;124(1):42-45. DOI: 10.1016/j.thromres.2008.10.004
  72. 72. Israels SJ, Rand ML, Michelson AD. Neonatal platelet function. Seminars in Thrombosis and Hemostasis. 2003;29(4):363-371. DOI: 10.1055/s-2003-42587
  73. 73. Schlagenhauf A, Schweintzger S, Birner-Gruenberger R, Leschnik B, Muntean W. Newborn platelets: Lower levels of protease-activated receptors cause hypoaggregability to thrombin. Platelets. 2010;21(8):641-647. DOI: 10.3109/09537104.2010.504869
  74. 74. Schlagenhauf A, Schweintzger S, Birner-Grünberger R, Leschnik B, Muntean W. Comparative evaluation of PAR1, GPIb-IX-V, and integrin αIIbβ3 levels in cord and adult platelets. Hämostaseologie. 2010;30(4a, Suppl 1):S164-S167
  75. 75. Revel-Vilk S. The conundrum of neonatal coagulopathy. Hematology. American Society of Hematology. Education Program;2012:450-454. DOI: 10.1182/asheducation-2012.1.450
  76. 76. Del Vecchio A, Stronati M, Franco C, Christensen RD. Bi-directional activation of inflammation and coagulation in septic neonates. Early Human Development. 2014;90:S22-S25. DOI: 10.1016/S0378-3782(14)70008-8
  77. 77. Kalagiri RR, Choudhury S, Carder T, Govande V, Beeram MR, Uddin MN. Neonatal Thrombocytopenia as a consequence of maternal preeclampsia. AJP Reports. 2016;06(01):e42-e47. DOI: 10.1055/s-0035-1565923
  78. 78. Burrows RF, Andrew M. Neonatal thrombocytopenia in the hypertensive disorders of pregnancy. Obstetrics and Gynecology. 1990;76(2):234-238
  79. 79. Kumar S, Haricharan K. Neonatal thrombocytopenia associated with gestational hypertension, preeclampsia and eclampsia: A case-control study. International Journal of Contemporary Pediatrics. 2016;3(1):16-21. DOI: 10.18203/2349-3291.ijcp20151385
  80. 80. Strauss T, Maayan-Metzger A, Simchen MJ, Morag I, Shenkmean B, Kuint J, et al. Impaired platelet function in neonates born to mothers with diabetes or hypertension during pregnancy. Klinische Pädiatrie. 2010;222(3):154-157. DOI: 10.1055/s-0030-1249092
  81. 81. Bhat YR, Cherian CS. Neonatal thrombocytopenia associated with maternal pregnancy induced hypertension. Indian Journal of Pediatrics. 2008;75(6):571-573. DOI: 10.1007/s12098-008-0110-x
  82. 82. Pritchard JA, Cunningham FG, Pritchard SA, Mason RA. How often does maternal preeclampsia-eclampsia incite thrombocytopenia in the fetus? Obstetrics and Gynecology. 1987;69(3Pt 1):292-295
  83. 83. Kuhne T, Ryan G, Blanchette V, Semple JW, Hornstein A, Mody M, et al. Platelet-surface glycoproteins in healthy and preeclamptic mothers and their newborn infants. Pediatric Research. 1996;40(6):876-880. DOI: 10.1203/00006450-199612000-00018
  84. 84. Yang J, Zhang H, Niu J, Mu X, Zhang X, Liu Y, et al. Impact of preeclampsia on megakaryocytopoesis and platelet homeostasis of preterm infants. Platelets. 2016;27(2):123-127. DOI: 10.3109/09537104.2015.1048213
  85. 85. Roberts I, Murray NA. Neonatal thrombocytopenia: Causes and management. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2003;88(5):F359-F364. DOI: 10.1136/fn.88.5.F359
  86. 86. Hutter D, Kingdom J, Jaeggi E. Causes and mechanisms of intrauterine hypoxia and its impact on the fetal cardiovascular system: A review. International Journal of Pediatrics. 2010;2010:401323. DOI: 10.1155/2010/401323
  87. 87. Cottrell MB, Jackson CW, McDonald TP. Hypoxia increases erythropoiesis and decreases thrombocytopoiesis in mice: A comparison of two mouse strains. Proceedings of the Society for Experimental Biology and Medicine. 1991;197(3):261-267. DOI: 10.3181/00379727-197-43253
  88. 88. Block-Abraham DM, Turan OM, Doyle LE, Kopelman JN, Atlas RO, Jenkins CB, et al. First-trimester risk factors for preeclampsia development in women initiating aspirin by 16 weeks of gestation. Obstetrics and Gynecology. 2014;123(3):611-617. DOI: 10.1097/AOG.0000000000000118
  89. 89. Roberge S, Odibo AO, Bujold E. Aspirin for the prevention of preeclampsia and intrauterine growth restriction. Clinics in Laboratory Medicine. 2016;36(2):319-329. DOI: 10.1016/j.cll.2016.01.013
  90. 90. Ferreira PMF, Gagliano-Juca T, Zaminelli T, Sampaio MF, Blackler RW, Trevisan MD, et al. Acetylsalicylic acid daily vs acetylsalicylic acid every 3 days in healthy volunteers: Effect on platelet aggregation, gastric mucosa, and prostaglandin E-2 synthesis. Journal of Clinical Pharmacology. 2016;56(7):862-868. DOI: 10.1002/jcph.685
  91. 91. Fitzgerald GA. Mechanisms of platelet activation—Thromboxane-a2 as an amplifying signal for other agonists. The American Journal of Cardiology. 1991;68(7):B11-B15. DOI: 10.1016/0002-9149(91)90379-y
  92. 92. Dasari R, Narang A, Vasishta K, Garewal G. Effect of maternal low dose aspirin on neonatal platelet function. Indian Pediatrics. 1998;35:507-512
  93. 93. Louden K, Pipkin FB, Heptinstall S, Fox S, Tuohy P, O'Callaghan C, et al. Neonatal platelet reactivity and serum thromboxane B2production in whole blood: The effect of maternal low dose aspirin. British Journal of Obstetrics and Gynaecology. 1994;101(3):203-208. DOI: 10.1111/j.1471-0528.1994.tb13110.x
  94. 94. Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Low-dose aspirin in pregnancy: Maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003;111(1):e77-e81. DOI: 10.1542/peds.111.1.e77
  95. 95. Bleyer WA, Breckenridge RT. Studies on the detection of adverse drug reactions in the newborn: II. The effects of prenatal aspirin on newborn hemostasis. Journal of the American Medical Association. 1970;213(12):2049-2053. DOI: 10.1001/jama.1970.03170380023004
  96. 96. Hammers AL, Sanchez-Ramos L, Kaunitz AM. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: A systematic review with metaanalysis. American Journal of Obstetrics and Gynecology. 2015;212(4):505.e1. DOI: 10.1016/j.ajog.2014.10.1091
  97. 97. Rhee E, Beiswenger T, Oguejiofor CE, James AH. The effects of magnesium sulfate on maternal and fetal platelet aggregation. The Journal of Maternal-Fetal & Neonatal Medicine. 2012;25(5):478-483. DOI: 10.3109/14767058.2011.584087
  98. 98. Brown RE, Rimsza LM, Pastos K, Young L, Saxonhouse MA, Bailey M, et al. Effects of sepsis on neonatal thrombopoiesis. Pediatric Research. 2008;64(4):399-404. DOI: 10.1203/PDR.0b013e318181ad49
  99. 99. Finkelstein Y, Shenkman B, Sirota L, Vishne TH, Dardik R, Varon D, et al. Whole blood platelet deposition on extracellular matrix under flow conditions in preterm neonatal sepsis. European Journal of Pediatrics. 2002;161(5):270-274. DOI: 10.1007/s00431-002-0938-4
  100. 100. Kara S, Emeksiz Z, Alioğlu B, Dallar Bilge Y. Effects of neonatal sepsis on thrombocyte tests. The Journal of Maternal-Fetal & Neonatal Medicine. 2016;29(9):1406-1408. DOI: 10.3109/14767058.2015.1049523
  101. 101. Sitaru AG, Speer CR, Holzhauer S, Obergfell A, Walter U, Grossmann R. Chorioamnionitis is associated with increased CD40L expression on cord blood platelets. Thrombosis and Haemostasis. 2005;94(6):1219-1223. DOI: 10.1160/th05-02-0127
  102. 102. Sheffield MJ, Lambert DK, Henry E, Christensen RD. Effect of ampicillin on the bleeding time of neonatal intensive care unit patients. Journal of Perinatology. 2010;30(8):527-530. DOI: 10.1038/jp.2009.192
  103. 103. Sheffield M, Lambert D, Baer V, Henry E, Butler A, Snow G, et al. Effect of ampicillin on bleeding time in very low birth-weight neonates during the first week after birth. Journal of Perinatology. 2011;31(7):477-480. DOI: 10.1038/jp.2010.154
  104. 104. Rennie JM, Doyle J, Cooke RW. Early administration of indomethacin to preterm infants. Archives of Disease in Childhood. 1986;61(3):233-238. DOI: 10.1136/adc.61.3.233
  105. 105. Corazza MS, Davis RF, Merritt TA, Bejar R, Cvetnic W. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. The Journal of Pediatrics. 1984;105(2):292-296. DOI: 10.1016/S0022-3476(84)80135-3
  106. 106. Friedman Z, Whitman V, Maisels MJ, Berman W Jr, Marks KH, Vesell ES. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. Journal of Clinical Pharmacology. 1978;18(5-6):272-279. DOI: 10.1002/j.1552-4604.1978.tb02446.x
  107. 107. Maher P, Lane B, Ballard R, Piecuch R, Clyman RI. Does indomethacin cause extension of intracranial hemorrhages: A preliminary study. Pediatrics. 1985;75(3):497-500
  108. 108. Sheffield MJ, Schmutz N, Lambert DK, Henry E, Christensen RD. Ibuprofen lysine administration to neonates with a patent ductus arteriosus: Effect on platelet plug formation assessed by in vivo and in vitro measurements. Journal of Perinatology. 2009;29(1):39-43. DOI: 10.1038/jp.2008.122
  109. 109. Tanriverdi S, Koroglu OA, Uygur O, Balkan C, Yalaz M, Kultursay N. The effect of inhaled nitric oxide therapy on thromboelastogram in newborns with persistent pulmonary hypertension. European Journal of Pediatrics. 2014;173(10):1381-1385. DOI: 10.1007/s00431-014-2325-3
  110. 110. Cheung P-Y, Salas E, Schulz R, Radomski MW. Nitric oxide and platelet function: Implications for neonatology. Seminars in Perinatology. 1997;21(5):409-417. DOI: 10.1016/S0146-0005(97)80006-7
  111. 111. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. The Journal of Pediatrics. 1998;132(4):731-734. DOI: 10.1016/S0022-3476(98)70370-1
  112. 112. Watala C, Chudzik A, Tchorzewski H, Gwozdzinski K. Impaired action of nitric oxide on blood platelets in premature newborns. Archives of Medical Science. 2008;4(3):315-323
  113. 113. Kannar V, Deepthi A, Kumar MLH, Junjegowda K, Mariyappa N. Effect of gestational age, prematurity and birth asphyxia on platelet indices in neonates. Journal of Clinical Neonatology. 2014;3(3):144-147. DOI: 10.4103/2249-4847.140399
  114. 114. Wasiluk A, Dabrowska M, Osada J, Jasinska E, Laudanski T, Redzko S. Platelet indices in SGA newborns. Advanced Medical Science. 2011;56(2):361-365. DOI: 10.2478/v10039-011-0030-2
  115. 115. Panova-Noeva M, Schulz A, Hermanns MI, Grossmann V, Pefani E, Spronk HMH, et al. Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: Results from the Gutenberg Health Study. Blood. 2016;127(2):251-259. DOI: 10.1182/blood-2015-07-660308
  116. 116. Ekin A, Gezer C, Kulhan G, Avci ME, Taner CE. Can platelet count and mean platelet volume during the first trimester of pregnancy predict preterm premature rupture of membranes? The Journal of Obstetrics and Gynaecology Research. 2015;41(1):23-28. DOI: 10.1111/jog.12484
  117. 117. Canpolat FE, Yurdakok M, Armangil D, Yigit S. Mean platelet volume in neonatal respiratory distress syndrome. Pediatrics International. 2009;51(2):314-316. DOI: 10.1111/j.1442-200X.2009.02820.x
  118. 118. Aly H, El Beshlawy A, Badrawi N, Mohsen L, Mansour E, Ramy N, et al. Thrombopoietin level is increased in the serum of asphyxiated neonates: A prospective controlled study. Journal of Perinatology. 2005;25(5):320-324. DOI: 10.1038/
  119. 119. Christensen RD, Baer VL, Yaish HM. Thrombocytopenia in late preterm and term neonates after perinatal asphyxia. Transfusion. 2015;55(1):187-196. DOI: 10.1111/trf.12777
  120. 120. Brus F, van Oeveren W, Okken A, Oetomo SB. Number and activation of circulating polymorphonuclear leukocytes and platelets are associated with neonatal respiratory distress syndrome severity. Pediatrics. 1997;99(5):672-680. DOI: 10.1542/peds.99.5.672
  121. 121. Ballin A, Koren G, Kohelet D, Burger R, Greenwald M, Bryan AC, et al. Reduction of platelet counts induced by mechanical ventilation in newborn infants. The Journal of Pediatrics. 1987;111(3):445-449. DOI: 10.1016/S0022-3476(87)80477-8
  122. 122. Postma S, Emara M, Obaid L, Johnson ST, Bigam DL, Cheung PY. Temporal platelet aggregatory function in hypoxic newborn piglets reoxygenated with 18%, 21%, and 100% oxygen. Shock. 2007;27(4):448-454. DOI: 10.1097/01.shk.0000245028.47106.92
  123. 123. Boutaybi N, Razenberg F, Smits-Wintjens V, van Zwet EW, Rijken M, Steggerda S, et al. Neonatal thrombocytopenia after perinatal asphyxia treated with hypothermia: A retrospective case control study. International Journal of Pediatrics. 2014;2014:760654. DOI: 10.1155/2014/760654
  124. 124. Oncel MY, Erdeve O, Calisici E, Oguz SS, Canpolat FE, Uras N, et al. The effect of whole-body cooling on hematological and coagulation parameters in asphyxic newborns. Pediatric Hematology and Oncology. 2013;30(3):246-252. DOI: 10.3109/08880018.2013.771240
  125. 125. Robinson TM, Kickler TS, Walker LK, Ness P, Bell W. Effect of extracorporeal membrane oxygenation on platelets in newborns. Critical Care Medicine. 1993;21(7):1029-1034. DOI: 10.1097/00003246-199307000-00018
  126. 126. Cheung PY, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Critical Care Medicine. 2000;28(7):2584-2590. DOI: 10.1097/00003246-200007000-00067
  127. 127. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Consensus definitions for sepsis and septic shock. Journal of the American Medical Association. 2016;315(8):801-810. DOI: 10.1001/jama.2016.0287
  128. 128. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: Versatile effector cells in hemostasis, inflammation, and the immune continuum. Seminars in Immunopathology. 2012;34(1):5-30. DOI: 10.1007/s00281-011-0286-4
  129. 129. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72. DOI: 10.4161/viru.26907
  130. 130. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. The American Journal of Medicine. 1976;61(5):585-589. DOI: 10.1016/0002-9343(76)90135-2
  131. 131. Thiery-Antier N, Binquet C, Vinault S, Meziani F, Boisramé-Helms J, Quenot J-P, et al. Is thrombocytopenia an early prognostic marker in septic shock? Critical Care Medicine. 2016;44(4):764-772. DOI: 10.1097/ccm.0000000000001520
  132. 132. Claushuis TAM, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PMC, Hoogendijk AJ, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood. 2016;127(24):3062-3072. DOI: 10.1182/blood-2015-11-680744
  133. 133. de Stoppelaar SF, van’t Veer C, Tvd P. The role of platelets in sepsis. Thrombosis and Haemostasis. 2014;112(4):666-677. DOI: 10.1160/TH14-02-0126
  134. 134. Deppermann C, Kubes P. Platelets and infection. Seminars in Immunology. 2016;28(6):536-545. DOI: 10.1016/j.smim.2016.10.005
  135. 135. Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Ündar A. Extracorporeal life support registry report 2008: Neonatal and pediatric cardiac cases. ASAIO Journal. 2009;55(1):111-116. DOI: 10.1097/MAT.0b013e318190b6f7
  136. 136. Groom RC, Froebe S, Martin J, Manfra MJ, Cormack JE, Morse C, et al. Update on pediatric perfusion practice in North America: 2005 survey. The Journal of Extra-Corporeal Technology. 2005;37(4):343-350
  137. 137. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal membrane oxygenation to aid cardiopulmonary resuscitation in infants and children. Circulation. 2007;116(15):1693-1700. DOI: 10.1161/CIRCULATIONAHA.106.680678
  138. 138. Zabrocki LA, Brogan TV, Statler KD, Poss WB, Rollins MD, Bratton SL. Extracorporeal membrane oxygenation for pediatric respiratory failure: Survival and predictors of mortality. Critical Care Medicine. 2011;39(2):364-370. DOI: 10.1097/CCM.0b013e3181fb7b35
  139. 139. Reed RC, Rutledge JC. Laboratory and clinical predictors of thrombosis and hemorrhage in 29 pediatric extracorporeal membrane oxygenation nonsurvivors. Pediatric and Developmental Pathology. 2010;13(5):385-392. DOI: 10.2350/09-09-0704-OA.1
  140. 140. Zwischenberger JB, Nguyen TT, Upp JR Jr, Bush PE, Cox CS Jr, Delosh T, et al. Complications of neonatal extracorporeal membrane oxygenation: Collective experience from the extracorporeal life support organization. The Journal of Thoracic and Cardiovascular Surgery. 1994;107(3):838-849
  141. 141. Kim HS, Cheon DY, Ha SO, Han SJ, Kim H-S, Lee SH, et al. Early changes in coagulation profiles and lactate levels in patients with septic shock undergoing extracorporeal membrane oxygenation. Journal of Thoracic Disease. 2018;10(3):1418-1430. DOI: 10.21037/jtd.2018.02.28
  142. 142. Fletcher Sandersjöö A, Bartek J, Thelin EP, Eriksson A, Elmi-Terander A, Broman M, et al. Predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: An observational cohort study. Journal of Intensive Care. 2017;5(1). DOI: 27. DOI: 10.1186/s40560-017-0223-2
  143. 143. Kreyer S, Muders T, Theuerkauf N, Spitzhüttl J, Schellhaas T, Schewe J-C, et al. Hemorrhage under veno-venous extracorporeal membrane oxygenation in acute respiratory distress syndrome patients: A retrospective data analysis. Journal of Thoracic Disease. 2017;9(12):5017-5029. DOI: 10.21037/jtd.2017.11.05
  144. 144. Lockie CJA, Gillon SA, Barrett NA, Taylor D, Mazumder A, Paramesh K, et al. Severe respiratory failure, extracorporeal membrane oxygenation, and intracranial hemorrhage. Critical Care Medicine. 2017;45(10):1642-1649. DOI: 10.1097/CCM.0000000000002579
  145. 145. Oliver WC. Anticoagulation and coagulation management for ECMO. Seminars in Cardiothoracic and Vascular Anesthesia. 2009;13(3):154-175. DOI: 10.1177/1089253209347384
  146. 146. Passmore MR, Fung YL, Simonova G, Foley SR, Diab SD, Dunster KR, et al. Evidence of altered haemostasis in an ovine model of venovenous extracorporeal membrane oxygenation support. Critical Care. 2017;21(1):191. DOI: 10.1186/s13054-017-1788-9
  147. 147. Lukito P, Wong A, Jing J, Arthur JF, Marasco SF, Murphy DA, et al. Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI. Journal of Thrombosis and Haemostasis. 2016;14(11):2253-2260. DOI: 10.1111/jth.13497
  148. 148. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Human Pathology. 1987;18(2):111-122. DOI: 10.1016/S0046-8177(87)80330-1
  149. 149. Ivanciu L, Krishnaswamy S, Camire RM. Imaging coagulation reactions in vivo. Thrombosis Research. 2012;129(Suppl 2):S54-S56. DOI: 10.1016/j.thromres.2012.02.034
  150. 150. Hase T, Sirajuddin S, Maluso P, Bangalore R, DePalma L, Sarani B. Platelet dysfunction in critically ill patients. Blood Coagulation and Fibrinolysis. 2017;28(6):475-478. DOI: 10.1097/mbc.0000000000000625
  151. 151. Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. Journal of Atherosclerosis and Thrombosis. 2015;22(3):265-271. DOI: 10.5551/jat.27268
  152. 152. Dewanjee MK, Wu SM, Kapadvanjwala M, De D, Dewanjee S, Gonzalez L, et al. Emboli from an extraluminal blood flow hollow fiber oxygenator with and without an arterial filter during cardiopulmonary bypass in a pig model. ASAIO Journal. 1996;42(6):1010-1018. DOI: 10.1097/00002480-199642060-00015
  153. 153. Meyer AD, Gelfond JA, Wiles AA, Freishtat RJ, Rais-Bahrami K. Platelet-derived microparticles generated by neonatal extracorporeal membrane oxygenation systems. ASAIO Journal. 2015;61(1):37-42. DOI: 10.1097/MAT.0000000000000164
  154. 154. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 1996;88(9):3456-3464
  155. 155. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, et al. Thrombocytopenia in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Journal of Critical Care. 2005;20(4):348-353. DOI: 10.1016/j.jcrc.2005.09.008
  156. 156. Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-1215. DOI: 10.1378/chest.13-0121
  157. 157. Abrams D, Baldwin MR, Champion M, Agerstrand C, Eisenberger A, Bacchetta M, et al. Thrombocytopenia and extracorporeal membrane oxygenation in adults with acute respiratory failure: A cohort study. Intensive Care Medicine. 2016;42(5):844-852. DOI: 10.1007/s00134-016-4312-9
  158. 158. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. Blood. 2014;123(8):1146-1151. DOI: 10.1182/blood-2013-02-435693
  159. 159. Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: An international survey. Pediatric Critical Care Medicine. 2013;14(2):E77-E84. DOI: 10.1097/PCC.0b013e31827127e4
  160. 160. Faraoni D, Levy JH. Algorithm-based management of bleeding in patients with extracorporeal membrane oxygenation. Critical Care. 2013;17(3):432. DOI: 10.1186/cc12682
  161. 161. Nair P, Hoechter DJ, Buscher H, Venkatesh K, Whittam S, Joseph J, et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. Journal of Cardiothoracic and Vascular Anesthesia. 2015;29(2):288-296. DOI: 10.1053/j.jvca.2014.06.006
  162. 162. Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004;19(5):283-288. DOI: 10.1191/0267659104pf759oa
  163. 163. Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D. Bivalirudin in venovenous extracorporeal membrane oxygenation. The Journal of Extra-Corporeal Technology. 2014;46(1):94-97
  164. 164. Gray B, Rintoul N. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Version 1.4. Extracorporeal Life Support Organization: Ann Arbor, MI, USA; 2017
  165. 165. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: An integrated approach. Seminars in Thrombosis and Hemostasis. 2014;40(1):106-114. DOI: 10.1055/s-0033-1363461
  166. 166. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics. 2002;109(1):E10. DOI: 10.1542/peds.109.1.e10
  167. 167. Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thrombosis and Haemostasis. 2004;91(4):719-724. DOI: 10.1160/TH03-09-0571
  168. 168. Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in paediatrics: Clinical characteristics, therapy and outcomes. Intensive Care Medicine. 2004;30(8):1615-1624. DOI: 10.1007/s00134-004-2315-4
  169. 169. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Seminars in Thrombosis and Hemostasis. 2001;27(3):293-299. DOI: 10.1055/s-2001-15259
  170. 170. Pollak U, Yacobobich J, Tamary H, Dagan O, Manor-Shulman O. Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: A case report and review of the literature. The Journal of Extra-Corporeal Technology. 2011;43(1):5-12
  171. 171. Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematology. American Society of Hematology. Education Program. 2013;2013(1):668-674. DOI: 10.1182/asheducation-2013.1.668
  172. 172. Warkentin TE. HIT paradigms and paradoxes. Journal of Thrombosis and Haemostasis. 2011;9(Suppl 1):105-117. DOI: 10.1111/j.1538-7836.2011.04322.x
  173. 173. Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, et al. Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. Journal of Critical Care. 2014;29(3):470.e7. DOI: 10.1016/j.jcrc.2014.02.004
  174. 174. Beiderlinden M, Treschan T, Görlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artificial Organs. 2007;31(6):461-465. DOI: 10.1111/j.1525-1594.2007.00388.x
  175. 175. Lequier L, Annich G, Al-Ibrahim O, Bembea M, Brodie D, Brogan T. ELSO Anticoagulation Guidelines. Ann Arbor, MI: Extracorporeal Life Support Organization; 2014
  176. 176. Ramasethu J, Luban N. Red blood cell transfusions in the newborn. Seminars in Neonatology. 1999;4(1):5-16
  177. 177. Del Vecchio A, Franco C, Petrillo F, D'Amato G. Neonatal transfusion practice: When do neonates need red blood cells or platelets? American Journal of Perinatology. 2016;33(11):1079-1084. DOI: 10.1055/s-0036-1586106
  178. 178. Sola-Visner M, Bercovitz RS. Neonatal platelet transfusions and future areas of research. Transfusion Medicine Reviews. 2016;304 SI:183-188. DOI: 10.1016/j.tmrv.2016.05.009
  179. 179. Cremer M, Sallmon H, Kling PJ, Buhrer C, Dame C. Thrombocytopenia and platelet transfusion in the neonate. Seminars in Fetal and Neonatal Medicine. 2016;21(1):10-18. DOI: 10.1016/j.siny.2015.11.001
  180. 180. Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter C. Frequency and mechanism of neonatal thrombocytopenia. The Journal of Pediatrics. 1986;108(5):749-755. DOI: 10.1016/S0022-3476(86)81059-9
  181. 181. Mehta P, Vasa R, Neumann L, Karpatkin M. Thrombocytopenia in the high-risk infant. The Journal of Pediatrics. 1980;97(5):791-794. DOI: 10.1016/S0022-3476(80)80272-1
  182. 182. Christensen RD, Henry E, Wiedmeier SE, Stoddard RA, Sola-Visner MC, Lambert DK, et al. Thrombocytopenia among extremely low birth weight neonates: Data from a multihospital healthcare system. Journal of Perinatology. 2006;26(6):348-353. DOI: 10.1038/
  183. 183. Andrew M, Vegh P, Caco C, Kirpalani H, Jefferies A, Ohlsson A, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premautre infants. The Journal of Pediatrics. 1993;123(2):285-291. DOI: 10.1016/S0022-3476(05)81705-6
  184. 184. Gunnink SF, Vlug R, Fijnvandraat K, van der Bom JG, Stanworth SJ, Lopriore E. Neonatal thrombocytopenia: Etiology, management and outcome. Expert Review of Hematology. 2014;7(3):387-395. DOI: 10.1586/17474086.2014.902301
  185. 185. Resch E, Hinkas O, Urlesberger B, Resch B. Neonatal thrombocytopenia-causes and outcomes following platelet transfusions. European Journal of Pediatrics. 2018;177(7):1045-1052. DOI: 10.1007/s00431-018-3153-7
  186. 186. Venkatesh V, Khan R, Curley A, New H, Stanworth S. How we decide when a neonate needs a transfusion. British Journal of Haematology. 2013;160(4):421-433. DOI: 10.1111/bjh.12095
  187. 187. Sparger KA, Assmann SF, Granger S, Winston A, Christensen RD, Widness JA, et al. Platelet transfusion practices among very-low-birth-weight infants. JAMA Pediatrics. 2016;170(7):687-694. DOI: 10.1001/jamapediatrics.2016.0507
  188. 188. Cremer M, Weimann A, Schmalisch G, Hammer H, Buhrer C, Dame C. Immature platelet values indicate impaired megakaryopoietic activity in neonatal early-onset thrombocytopenia. Thrombosis and Haemostasis. 2010;103(5 SI):1016-1021. DOI: 10.1160/TH09-03-0148
  189. 189. MacQueen BC, Christensen RD, Henry E, Romrell AM, Pysher TJ, Bennett ST, et al. The immature platelet fraction: Creating neonatal reference intervals and using these to categorize neonatal thrombocytopenias. Journal of Perinatology. 2017;37(7):834-838. DOI: 10.1038/jp.2017.48
  190. 190. Sparger K, Deschmann E, Sola-Visner M. Platelet transfusions in the neonatal intensive care unit. Clinics in Perinatology. 2015;42(3):613-623. DOI: 10.1016/j.clp.2015.04.009
  191. 191. Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. Journal of Perinatology. 2009;29(2):130-136. DOI: 10.1038/jp.2008.141
  192. 192. Poryo M, Boeckh JC, Gortner L, Zemlin M, Duppre P, Ebrahimi-Fakhari D, et al. Ante-, peri- and postnatal factors associated with intraventricular hemorrhage in very premature infants. Early Human Development. 2018;116:1-8. DOI: 10.1016/j.earlhumdev.2017.08.010
  193. 193. Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, et al. Randomized trial of platelet-transfusion thresholds in neonates. The New England Journal of Medicine. 2019;380(3):242-251. DOI: 10.1056/NEJMoa1807320
  194. 194. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. Guidelines on transfusion for fetuses, neonates and older children. British Journal of Haematology. 2016;175(5):784-828. DOI: 10.1111/bjh.14233
  195. 195. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfusion. 2009;7(2):132-150. DOI: 10.2450/2009.0005-09
  196. 196. Cremer M, Sola-Visner M, Roll S, Josephson CD, Yilmaz Z, Buhrer C, et al. Platelet transfusions in neonates: Practices in the United States vary significantly from those in Austria, Germany, and Switzerland. Transfusion. 2011;51(12):2634-2641. DOI: 10.1111/j.1537-2995.2011.03208.x
  197. 197. Josephson CD, Su LL, Christensen RD, Hillyer CD, Castillejo MI, Emory MR, et al. Platelet transfusion practices among neonatologists in the United States and Canada: Results of a survey. Pediatrics. 2009;123(1):278-285. DOI: 10.1542/peds.2007-2850
  198. 198. Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD. Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. Journal of Perinatology. 2007;27(12):790-796. DOI: 10.1038/
  199. 199. Forman KR, Wong E, Gallagher M, McCarter R, Luban NLC, Massaro AN. Effect of temperature on thromboelastography and implications for clinical use in newborns undergoing therapeutic hypothermia. Pediatric Research. 2014;75(5):663-669. DOI: 10.1038/pr.2014.19
  200. 200. Chakkarapani E, Davis J, Thoresen M. Therapeutic hypothermia delays the C-reactive protein response and suppresses white blood cell and platelet count in infants with neonatal encephalopathy. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2014;99(6):F485-F463. DOI: 10.1136/archdischild-2013-305763
  201. 201. Christensen RD, Sheffield MJ, Lambert DK, Baer VL. Effect of therapeutic hypothermia in neonates with hypoxic-ischemic encephalopathy on platelet function. Neonatology. 2012;101(2):91-94. DOI: 10.1159/000329818

Written By

Ijeoma Esiaba, Iman Mousselli, Giulia M. Faison, Danilyn M. Angeles and Danilo S. Boskovic

Submitted: 13 September 2018 Reviewed: 07 May 2019 Published: 02 September 2019